长链非编码RNA调控泛素化的机制及其在癌症中的研究进展

刘汉艳; 刘珂; 张芬; 刘俊江; 黄革; 李娜

doi:10.16766/j.cnki.issn.1674-4152.004424

长链非编码RNA调控泛素化的机制及其在癌症中的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.004424

遵义医科大学第二附属医院妇产科，贵州遵义 563000

基金项目:

贵州省科技厅基础研究计划(自然科学)重点项目黔科合基础ZD〔2025〕023

遵义医科大学第二附属医院博士科研启动基金项目 BQ-2024-001

详细信息

通讯作者:
李娜，E-mail: foxlina2008@163.com

中图分类号: R730.2
计量
- 文章访问数: 15
- HTML全文浏览量: 8
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-28
- 网络出版日期: 2026-06-02

The mechanism of LncRNA regulating ubiquitination and its research progression in cancer

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, China

摘要

摘要: 长链非编码RNA(long non-coding RNA, LncRNA)是一类长度超过200个核苷酸、缺乏开放阅读框、主要由RNA聚合酶Ⅱ转录生成的RNA分子，在表观遗传、基因调控、蛋白质翻译后修饰等过程中发挥重要作用。泛素化作为一种关键的蛋白质翻译后修饰机制，通过对细胞内靶蛋白的特异性修饰，调控蛋白质的稳定性、活性及降解，与细胞信号通路、代谢重编程、免疫逃逸等多种生物学过程密切相关。研究表明，LncRNA通过调控泛素酶的活性、与靶蛋白或去泛素酶相互作用等多种途径，影响泛素化过程，如LncRNA可作为分子支架促进泛素化复合物的形成，或直接与泛素酶结合改变其催化活性，维持靶蛋白稳定并抑制其泛素化等。在癌症中，LncRNA通过影响信号通路的激活或抑制癌抑制因子如p53的表达水平，从而促进或抑制癌细胞的增殖。某些LncRNA可通过调控肿瘤微环境中的免疫相关因子或代谢酶的泛素化，帮助癌细胞逃避免疫监视或调整能量代谢，为癌细胞的生存和扩散提供支持，这表明LncRNA调控蛋白质泛素化的机制是复杂多样的。本文旨在探讨LncRNA在调控蛋白质泛素化中的具体机制及其在癌症中的作用，为探索癌症发展机制和药物靶点提供新的视角。
- 长链非编码RNA /
- 泛素化 /
- 癌症 /
- 调控机制
Abstract: Long non-coding RNAs (LncRNAs) are a class of RNA molecules that surpass 200 nucleotides in length, distinguished by the absence of an open reading frame and primarily transcribed by RNA polymerase Ⅱ. LncRNAs have been demonstrated to play pivotal roles in epigenetic regulation, gene expression modulation, and protein post-translational modifications. Ubiquitination, a critical post-translational modification mechanism, regulates protein stability, activity and degradation by changing intracellular target proteins. A plethora of biological activities, encompassing cell signaling pathways, metabolic reprogramming, immunological evasion and oncogenesis, are intricately linked to the ubiquitination process. Research has demonstrated that LncRNAs influence the process by modulating ubiquitinases and engaging with substrate proteins or deubiquitinases. For instance, LncRNAs have been shown to function as molecular scaffolding to help ubiquitinated complexes form or directly interact with ubiquitinases to modulate their catalytic activity, stabilizing and inhibiting target protein ubiquitination. By activating signaling pathways or repressing tumor suppressors such as p53, LncRNAs can help or hinder cancer cells proliferation. Furthermore, certain LncRNAs have been found to regulate the ubiquitination of immune-related molecules or metabolic enzymes inside the tumor microenvironment, thus facilitating cancer ' s evasion of immune surveillance or modifying energy metabolism to enhance the survival and dissemination of cancer cells. The present review aims to elucidate how LncRNAs influence protein ubiquitination and their roles in cancer, thereby providing new insights into searching mechanisms of cancer development and screening the therapeutic targets.
- LncRNA /
- Ubiquitination /
- Cancer /
- Regulatory mechanism

HTML全文

参考文献(41)

[1]	HAN J, NIE M L, CHEN C, et al. SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis[J]. Cancer Commun (Lond), 2022, 42(11): 1141-1161. doi: 10.1002/cac2.12367
[2]	MATTICK J S, AMARAL P P, CARNINCI P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations[J]. Nat Rev Mol Cell Biol, 2023, 24(6): 430-447.
[3]	FERRER J, DIMITROVA N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance[J]. Nat Rev Mol Cell Biol, 2024, 25(5): 396-415. doi: 10.1038/s41580-023-00694-9
[4]	MUCH C, LASDA E L, PEREIRA I T, et al. The temporal dynamics of lncRNA Firre-mediated epigenetic and transcriptional regulation[J]. Nat Commun, 2024, 15(1): 6821. DOI: 10.1038/s41467-024-50402-0.
[5]	WERNER A, KANHERE A, WAHLESTEDT C, et al. Natural antisense transcripts as versatile regulators of gene expression[J]. Nat Rev Genet, 2024, 25(10): 730-744.
[6]	ZHANG Y G. LncRNA-encoded peptides in cancer[J]. J Hematol Oncol, 2024, 17(1): 66. DOI: 10.1186/s13045-024-01591-0.
[7]	DAGAR G, KUMAR R, YADAV K K, et al. Ubiquitination and deubiquitination: implications on cancer therapy[J]. Biochim Biophys Acta Gene Regul Mech, 2023, 1866(4): 1949-1979.
[8]	YOU J R, WEN Z J, TIAN J W, et al. Crosstalk between ubiquitin ligases and ncRNAs drives cardiovasculardisease progression[J]. Front Immunol, 2024, 15: 1335519. DOI: 10.3389/fimmu.2024.1335519.
[9]	LIU F F, CHEN J Y, LI K, et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches[J]. Mol Cancer, 2024, 23(1): 148. DOI: 10.1186/s12943-024-02046-3.
[10]	RAPE M. Ubiquitylation at the crossroads of development and disease[J]. Nat Rev Mol Cell Biol, 2018, 19(1): 59-70.
[11]	YOON J H, ABDELMOHSEN K, KIM J, et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination[J]. Nat Commun, 2013, 4: 2939. DOI: 10.1038/ncomms3939.
[12]	XIN Z C, HU C Y, ZHANG C F, et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis[J]. Redox Biol, 2024, 77: 103362. DOI: 10.1016/j.redox.2024.103362.
[13]	GUO Q N, LI Y H, ZHANG Y M, et al. LncRNA NRON promotes tumorigenesis by enhancing MDM2 activity toward tumor suppressor substrates[J]. EMBO J, 2023, 42(16): e112414. DOI: 10.15252/embj.2022112414.
[14]	孙飞涵, 李聃宁, 杨华, 等. LncRNA-CCRR通过调控UBA6影响钠通道泛素化进而调控心梗后心律失常[J]. 中国药理学通报, 2024, 40(8): 1437-1446. SUN F H, LI D N, YANG H, et al. LncRNA-CCRR regulates arrhythmia induced by myocardial infarction by affecting sodium channel ubiquitination via UBA6[J]. Chinese Pharmacological Bulleti, 2024, 40(8): 1437-1446.
[15]	DINDOT S V, CHRISTIAN S, MURPHY W J, et al. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript[J]. Sci Transl Med, 2023, 15(688): eabf4077. DOI: 10.1126/scitranslmed.abf4077.
[16]	VIHMA H, LI K, WELTON-ARNDT A, et al. Ube3a unsilencer for the potential treatment of Angelman syndrome[J]. Nat Commun, 2024, 15(1): 5558. DOI: 10.1038/s41467-024-49788-8.
[17]	GAO G B, CHEN L, PAN J F, et al. LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer[J]. Cancer Lett, 2024, 590: 216826. DOI: 10.1016/j.canlet.2024.216826.
[18]	LI M, SHI M K, HU C Y, et al. MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation[J]. Oncogene, 2021, 40(22): 3870-3884. doi: 10.1038/s41388-021-01816-3
[19]	CAO C C, LI A L, XU C J, et al. Engineering artificial non-coding RNAs for targeted protein degradation[J]. Nat Chem Biol, 2024. DOI: 10.1038/s41589-024-01719-w.
[20]	ZHANG N S, WANG B W, MA C, et al. LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization[J]. J Exp Clin Cancer Res, 2023, 42(1): 89. DOI: 10.1186/s13046-023-02654-9.
[21]	LI L L, ZHOU A D, WEI Y J, et al. Critical role of lncEPAT in coupling dysregulated EGFR pathway and histone H₂A deubiquitination during glioblastoma tumorigenesis[J]. Sci Adv, 2022, 8(40): eabn2571. DOI: 10.1126/sciadv.abn2571.
[22]	李喜梅, 林丽, 毛郁蕾, 等. 长链非编码RNA BCYRN1对SKOV3细胞恶性生物学行为的影响[J]. 中华全科医学, 2021, 19(10): 1658-1661, 1728. doi: 10.16766/j.cnki.issn.1674-4152.002135 LI X M, LIN L, MAO Y L, et al. Effect of long chain noncoding RNA BCYRN1 on malignant biological behavior of SKOV3 cells[J]. Chinese Journal of General Practice, 2021, 19(10): 1658-1661, 1728. doi: 10.16766/j.cnki.issn.1674-4152.002135
[23]	WU Y, GUO Q H, JU X Z, et al. HNRNPH1 -stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway[J]. Oncogene, 2021, 40(29): 4770-4782. doi: 10.1038/s41388-021-01884-5
[24]	WU Y B, LI S Y, LIU J Y, et al. Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2/β-catenin pathway[J]. Cell Death Dis, 2023, 14(10): 696. DOI: 10.1038/s41419-023-06214-z.
[25]	PEUGET S, ZHOU X, SELIVANOVA G. Translating p53-based therapies for cancer into the clinic[J]. Nat Rev Cancer, 2024, 24(3): 192-215.
[26]	HASSIN O, OREN M. Drugging p53 in cancer: one protein, many targets[J]. Nat Rev Drug Discov, 2023, 22(2): 127-144.
[27]	YUAN J, OFENGEIM D. A guide to cell death pathways[J]. Nat Rev Mol Cell Biol, 2024, 25(5): 379-395.
[28]	ZHOU M, CHENG H, FU Y L, et al. Long noncoding RNA DARS-AS1 regulates TP53 ubiquitination and affects ovarian cancer progression by modulation miR-194-5p/ RBX1 axis[J]. J Biochem Mol Toxicol, 2021, 35(10): e22865. DOI: 10.1002/jbt.22865.
[29]	HUANG G Q, XIANG Z X, WU H T, et al. The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination[J]. Int J Biol Sci, 2022, 18(4): 1415-1433.
[30]	曾薇, 刘翼, 李文婷, 等. 结直肠癌中差异性表达的外泌体LncRNA功能富集及通路分析[J]. 中华全科医学, 2022, 20(1): 141-143, 164. doi: 10.16766/j.cnki.issn.1674-4152.002297 ZENG W, LIU Y, LI W T, et al. Functional enrichment and pathway analysis of differential expression of exosome lncRNA in colorectal cancer[J]. Chinese Journal of General Practice, 2022, 20(1): 141-143, 164. doi: 10.16766/j.cnki.issn.1674-4152.002297
[31]	WANG X, CHENG H, ZHAO J, et al. Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer[J]. Mol Cancer, 2022, 21(1): 210. DOI: 10.1186/s12943-022-01675-w.
[32]	SUN Y, ZHANG H, MA R R, et al. ETS-1-activated LINC01016 over-expression promotes tumor progression via suppression of RFFL-mediated DHX9 ubiquitination degradation in breast cancers[J]. Cell Death Dis, 2023, 14(8): 507. DOI: 10.1038/s41419-023-06016-3.
[33]	ZHANG Z, LU Y X, LIU F, et al. LncRNA BREA2 promotes metastasis by disrupting the WWP2-mediatedubiquitination of Notch1[J]. Proc Natl Acad Sci USA, 2023, 120(8): e2206694120. DOI: 10.1073/pnas.2206694120.
[34]	XU L L, ZOU C, ZHANG S S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors[J]. J Hematol Oncol, 2022, 15(1): 87. DOI: 10.1186/s13045-022-01307-2.
[35]	LIN X, KANG K, CHEN P, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers[J]. Mol Cancer, 2024, 23(1): 108. DOI: 10.1186/s12943-024-02023-w.
[36]	SUN Z J, MAI H X, XUE C Y, et al. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination[J]. J Immunother Cancer, 2023, 11(12): e007415. DOI: 10.1136/jitc-2023-007415.
[37]	HU Q S, YE Y Q, CHAN L C, et al. Oncogenic LncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression[J]. Nat Immunol, 2019, 20(7): 835-851.
[38]	ZHANG J, OUYANG F, GAO A B, et al. ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment[J]. Mol Cancer, 2024, 23(1): 94. DOI: 10.1186/s12943-024-02009-8.
[39]	HE B Y, PAN H L, ZHENG F Q, et al. Long noncoding RNA LINC00930 promotes PFKFB3 -mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1): 77. DOI: 10.1186/s13046-022-02282-9.
[40]	ZENG Z, WANG J, XU F Y, et al. The m6A modification-mediated positive feedback between glycolytic LncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma[J]. Int J Biol Sci, 2024, 20(5): 1744-1762.
[41]	CHEN K L, HUANG S W, YAO J J, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein[J]. Drug Resist Updat, 2024, 76: 101-111.